Efficacy And Safety of Olatorepatide in Adults With Overweight or Obesity Without Diabetes

Brief summary (registry, in English)

This study will test olatorepatide (study drug) to determine whether it can help treat overweight or obesity. In this study we will test how safe and how well olatorepatide works compared to placebo in people who are overweight or obese but do not have diabetes. The study is looking at: * How well the study drug works * How the body and blood and urine biomarkers change after taking the study drug, which can help researchers understand why the study drug may work better in some people than in others * What side effects the study drug might cause * How much of the study drug is in the blood at different times * If the body makes antibodies to the study drug this may cause the study drug to not work as well

What you commit to

• Study type: Interventional · Phase 3
• Planned participants: 3000
• From 18 Nov 2026 to the primary completion date, 19 Dec 2028
• 60 sites in 5 countries
• Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Who the study is looking for

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (60)

Sites in registry order. Pick your city on the disease page to sort them by distance.